摘要
体内和体外研究显示凝溶胶蛋白是一个抵抗淀粉样蛋白。曲古抑菌素A(TSA),是一个组蛋白去乙酰化酶抑制剂,促进凝溶胶蛋白的表达。纤维化的淀粉样蛋白(Aβ)是AD患者脑中淀粉斑块的核心成分。我们研究了TSA对凝溶胶蛋白的水平,淀粉样前蛋白(APP)、蛋白水解酶(γ-分泌酶和β-分泌酶)是Aβ产生的主要原因;Aβ清除酶,即脑啡肽酶(NEP)和胰岛素降解酶(IDE);淀粉样蛋白负载的双转基因(Tg)APPswe/PS1δE9 AD大鼠模型。腹腔内注射TSA2个月(9-11月年龄)导致HDAC活性的降低,与未经处理的大鼠相比, AD Tg大鼠模型的海马和大脑皮层凝溶胶蛋白的水平增长了,TSA同样增加了脑中γ-分泌酶和β-分泌酶的活性水平。但是,TSA对 NEP和IDE在脑中的活性或者表达水平显示任何的效果。此外,TSA治疗的AD Tg大鼠海马区和大脑皮层上淀粉样蛋白的负载没有任何变化(淀粉样蛋白斑块出现的检测区域的比例),这说明TSA治疗并不能导致淀粉样蛋白的负载的降低。有趣的是,TSA能够阻止新的淀粉样蛋白的沉积但是了已有斑块的面积。TSA治疗没有导致脑中任何的凋亡。这些结果说明,TSA增加了凝溶胶蛋白在脑中的表达,TSA的多向性作用减低了凝溶胶蛋白在AD Tg 大鼠中的抗-淀粉样蛋白沉积作用。
关键词: 阿尔茨海默病,淀粉样蛋白斑块,凝溶胶蛋白,组蛋白去乙酰化酶,胰岛素降解酶,脑啡肽酶,分泌酶,转基因大鼠,曲古抑菌素A
Current Alzheimer Research
Title:Effect of Trichostatin A on Gelsolin Levels, Proteolysis of Amyloid Precursor Protein, and Amyloid Beta-Protein Load in the Brain of Transgenic Mouse Model of Alzheimer's Disease
Volume: 11 Issue: 10
Author(s): Wenzhong Yang, Abha Chauhan, Jerzy Wegiel, Izabela Kuchna, Feng Gu and Ved Chauhan
Affiliation:
关键词: 阿尔茨海默病,淀粉样蛋白斑块,凝溶胶蛋白,组蛋白去乙酰化酶,胰岛素降解酶,脑啡肽酶,分泌酶,转基因大鼠,曲古抑菌素A
摘要: In vivo and in vitro studies have shown that gelsolin is an anti-amyloidogenic protein. Trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, promotes the expression of gelsolin. Fibrillized amyoid beta-protein (Aβ) is a key constituent of amyloid plaques in the brains of patients with Alzheimer’s disease (AD). We studied the effects of TSA on the levels of gelsolin; amyloid precursor protein (APP); proteolytic enzymes (γ-secretase and β-secretase) responsible for the production of Aβ; Aβ-cleaving enzymes, i.e., neprilysin (NEP) and insulin-degrading enzyme (IDE); and amyloid load in the double transgenic (Tg) APPswe/PS1δE9 mouse model of AD. Intraperitoneal injection of TSA for two months (9–11 months of age) resulted in decreased activity of HDAC, and increased levels of gelsolin in the hippocampus and cortex of the brain in AD Tg mice as compared to vehicle-treated mice. TSA also increased the levels of γ-secretase and β-secretase activity in the brain. However, TSA did not show any effect on the activities or the expression levels of NEP and IDE in the brain. Furthermore, TSA treatment of AD Tg mice showed no change in the amyloid load (percent of examined area occupied by amyloid plaques) in the hippocampus and cortex, suggesting that TSA treatment did not result in the reduction of amyloid load. Interestingly, TSA prevented the formation of new amyloid deposits but increased the size of existing plaques. TSA treatment did not cause any apoptosis in the brain. These results suggest that TSA increases gelsolin expression in the brain, but the pleiotropic effects of TSA negate the anti-amyloidogenic effect of gelsolin in AD Tg mice.
Export Options
About this article
Cite this article as:
Wenzhong Yang, Abha Chauhan, Jerzy Wegiel, Izabela Kuchna, Feng Gu and Chauhan Ved, Effect of Trichostatin A on Gelsolin Levels, Proteolysis of Amyloid Precursor Protein, and Amyloid Beta-Protein Load in the Brain of Transgenic Mouse Model of Alzheimer's Disease, Current Alzheimer Research 2014; 11 (10) . https://dx.doi.org/10.2174/1567205011666141107125531
DOI https://dx.doi.org/10.2174/1567205011666141107125531 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Multidimensional Ophthalmic Nanosystems for Molecular Detection and Therapy of Eye Disorders
Current Pharmaceutical Design Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry Comparison of Three Radiochemical Purity Control Methods of 99mTc-macroaggregated Albumin
Current Radiopharmaceuticals The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Delivery of Therapeutic Proteins: Challenges and Strategies
Current Drug Targets Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Modern Perspectives on the Structure, Function and Evolution of the Relaxin-Like Peptides and their Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?
Current Pharmaceutical Design The Influence of DMPK as an Integrated Partner in Modern Drug Discovery
Current Drug Metabolism COX-2, Cell Proliferation and PMA in Head-and-Neck Cancer Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Meet Our Editorial Board Member
Endocrine, Metabolic & Immune Disorders - Drug Targets An Updated Organic Classification of Tyrosinase Inhibitors on Melanin Biosynthesis
Current Organic Chemistry Lack of Association between Genetic Polymorphism of Circadian Genes (PER2, PER3, CLOCK and OX2R) with Late Onset Depression and Alzheimer's Disease in a Sample of a Brazilian Population (Circadian Genes, Late-Onset Depression and Alzheimer's Disease)
Current Alzheimer Research Research in Rare Diseases - When Less is More
Current Medicinal Chemistry Expression and Functions of LRP-2 in Central Nervous System: Progress in Understanding its Regulation and the Potential Use for Treatment of Neurodegenerative Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Implications for CNS Repair of Redox Modulation of Cell Survival, Division and Differentiation
Current Alzheimer Research Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy
Current Cancer Drug Targets